Does 5mg Mounjaro Help You Lose More Weight?

2.5mg is a tolerability starter: it reduces early side effects rather than producing the treatment's full effect on appetite and weight.
5mg is the first therapeutic dose in the licensed UK schedule, where clinical weight loss commonly becomes noticeable.
Weight loss at 5mg still varies substantially between individuals, depending on diet, activity, and how your body responds to tirzepatide.
Dose increases follow the prescriber's assessment — evidence of response and tolerability both matter before moving higher.

Moving from 2.5mg to 5mg Mounjaro does tend to increase weight loss for most people. The 2.5mg starting dose is designed to help your body adjust to tirzepatide, not to drive significant fat reduction; 5mg is where meaningful appetite suppression typically begins. That said, individual responses vary, and a prescriber decides when a dose increase is appropriate. Mounjaro is a prescription-only medicine, so any change to your dose is a clinical decision, not a self-directed one.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

What the evidence and the licensed schedule tell you about 5mg Mounjaro and weight loss

You've just been moved to 5mg — here's what's actually changing

Picture it: you've had four weeks on the 2.5mg pen, the nausea settled down, and your prescriber has now moved you to 5mg. The natural question is whether the scales will finally start to shift. The short answer is yes, more so than on 2.5mg, but the mechanism matters, because it explains why patience is still required.

Tirzepatide works by activating two gut-hormone receptors, GIP and GLP-1, which slow gastric emptying, reduce appetite signals, and influence how the body handles blood sugar. At 2.5mg, the primary job is letting your system acclimatise: gastrointestinal side effects are common at the start, and the low dose keeps them manageable. At 5mg, the same dual-receptor effect is meaningfully stronger. Most people notice appetite suppression becoming more consistent, and that reduced intake is what drives greater weight reduction over subsequent weeks.

It rarely happens overnight. Tirzepatide builds in your system across the four-week pen cycle, and the visible effect on weight often lags several weeks behind the dose change. If you were hoping for an immediate jump after your first 5mg injection, that expectation is worth resetting. The full Mounjaro overview has more on how the titration schedule works from 2.5mg all the way through to the higher doses.

Why 5mg produces more weight loss than 2.5mg, and where the ceiling is

Clinical trials confirm a clear dose-response pattern across the licensed Mounjaro range. In SURMOUNT-1, published in the New England Journal of Medicine, participants taking higher doses consistently achieved greater average weight reductions: around 15% body weight at 5mg over 72 weeks, compared with progressively larger reductions as doses climbed toward 15mg (where average loss approached 20–21%). That 5mg figure is still clinically meaningful (roughly 12–15kg for someone starting at 90kg) but it's not the ceiling.

The implication is straightforward. If you tolerate 5mg well and your prescriber is satisfied with your progress, there is further potential weight loss available at 7.5mg and beyond. The question of whether to move up isn't purely about wanting more, it's about tolerability, clinical evidence of response, and whether a higher dose is appropriate for your health picture. The page on whether higher doses produce more weight loss covers that pattern in more detail.

One practical note worth making here: your pen goes from the fridge into your routine, and keeping that routine consistent, same day each week, same storage conditions, actually matters for how stable your drug levels stay. Consistency in administration supports consistency in effect.

When 5mg might not feel like it's doing enough, and what to do about it

Some people find their weight loss slows or plateaus while on 5mg. This is not unusual and doesn't mean treatment has stopped working entirely, but it's worth understanding the likely causes before drawing conclusions. A common one is dietary adaptation: as appetite suppression becomes familiar, some people unconsciously eat more than they did in the first weeks. Another is that 5mg is simply not the dose at which your individual physiology responds most strongly.

The question of what results to expect at 5mg depends heavily on how long you've been at that dose. NICE guidance on tirzepatide notes that if less than 5% weight loss is achieved after six months at the highest tolerated dose, the appropriateness of continuing should be reviewed, so early plateau at 5mg, before a full titration course, is a different situation from sustained non-response at the treatment's maximum. Your prescriber is the right person to interpret your specific progress.

Unhelpfully, there's a lot of online content suggesting people should push for dose increases quickly. The clinical rationale runs the other way: moving too fast through doses increases the risk of side effects without necessarily improving outcomes faster. The 5mg Mounjaro page goes into more detail on what to expect at this specific dose. For questions about what comes next in the schedule, the 7.5mg dose overview is worth reading once your prescriber raises the topic. And if you're thinking about the cost implications of staying on treatment long-term, the Mounjaro cost context page sets out what private treatment actually involves.

The NHS's patient information for tirzepatide is also a clear, trustworthy reference for what to expect at each stage, and it's worth reading alongside whatever your prescriber tells you.

If you'd like a clinical assessment of where you are in the titration schedule, or you're considering starting Mounjaro for the first time, start your free consultation with our prescribers.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions